Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Shanghai Haohai Biological Technology

DB:5HB
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
5HB
DB
HK$13B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Shanghai Haohai Biological Technology Co., Ltd. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Shanghai Haohai Biological Technology has significant price volatility in the past 3 months.
5HB Share Price and Events
7 Day Returns
8.8%
DB:5HB
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-42.5%
DB:5HB
-7.4%
DE Biotechs
-14.2%
DE Market
5HB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Shanghai Haohai Biological Technology (5HB) 8.8% -13.9% -34.1% -42.5% -21.8% -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 5HB underperformed the Biotechs industry which returned -7.4% over the past year.
  • 5HB underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
5HB
Industry
5yr Volatility vs Market

5HB Value

 Is Shanghai Haohai Biological Technology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Shanghai Haohai Biological Technology to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Shanghai Haohai Biological Technology.

DB:5HB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:5HB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.3%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 25%) (0.68%))
1.036
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.036 * 6.33%)
6.17%

Discounted Cash Flow Calculation for DB:5HB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Shanghai Haohai Biological Technology is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:5HB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 6.17%)
2020 130.73 Est @ 18.25% 123.13
2021 147.27 Est @ 12.66% 130.66
2022 160.15 Est @ 8.74% 133.83
2023 169.76 Est @ 6% 133.62
2024 176.69 Est @ 4.08% 131.00
2025 181.54 Est @ 2.74% 126.78
2026 184.81 Est @ 1.8% 121.57
2027 186.93 Est @ 1.14% 115.82
2028 188.21 Est @ 0.68% 109.84
2029 188.89 Est @ 0.36% 103.83
Present value of next 10 years cash flows CN¥1,230.00
DB:5HB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥188.89 × (1 + -0.39%) ÷ (6.17% – -0.39%)
CN¥2,869.66
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥2,869.66 ÷ (1 + 6.17%)10
CN¥1,577.44
DB:5HB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥1,230.00 + CN¥1,577.44
CN¥2,807.44
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥2,807.44 / 177.83
CN¥15.79
DB:5HB Discount to Share Price
Calculation Result
Exchange Rate CNY/HKD
(Reporting currency to currency of SEHK:6826)
1.097
Value per Share
(HKD)
= Value per Share in CNY x Exchange Rate (CNY/HKD)
= CN¥15.79 x 1.097
HK$17.32
Non-primary Listing Adjustment Factor 1 share in DB:5HB represents 0.1163x of SEHK:6826
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.1163x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (HKD) x Listing Adjustment Factor
= HK$ 17.32 x 0.1163
€2.01
Value per share (EUR) From above. €2.01
Current discount Discount to share price of €3.46
= -1 x (€3.46 - €2.01) / €2.01
-71.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Shanghai Haohai Biological Technology is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Shanghai Haohai Biological Technology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Shanghai Haohai Biological Technology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:5HB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CNY CN¥2.27
SEHK:6826 Share Price ** SEHK (2020-04-08) in HKD HK$29.75
SEHK:6826 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.911 CN¥27.11
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Shanghai Haohai Biological Technology.

DB:5HB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:6826 Share Price ÷ EPS (both in CNY)

= 27.11 ÷ 2.27

11.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Shanghai Haohai Biological Technology is good value based on earnings compared to the Europe Biotechs industry average.
  • Shanghai Haohai Biological Technology is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Shanghai Haohai Biological Technology's expected growth come at a high price?
Raw Data
DB:5HB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 11.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
27.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

DB:5HB PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 11.94x ÷ 27.3%

0.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Shanghai Haohai Biological Technology is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Shanghai Haohai Biological Technology's assets?
Raw Data
DB:5HB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CNY CN¥23.33
SEHK:6826 Share Price * SEHK (2020-04-08) in HKD HK$29.75
SEHK:6826 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.911 CN¥27.11
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:5HB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:6826 Share Price ÷ Book Value per Share (both in CNY)

= 27.11 ÷ 23.33

1.16x

* Primary Listing of Shanghai Haohai Biological Technology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Shanghai Haohai Biological Technology is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Shanghai Haohai Biological Technology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Shanghai Haohai Biological Technology has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

5HB Future Performance

 How is Shanghai Haohai Biological Technology expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Shanghai Haohai Biological Technology expected to grow at an attractive rate?
  • Shanghai Haohai Biological Technology's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Shanghai Haohai Biological Technology's earnings growth is expected to exceed the Germany market average.
  • Shanghai Haohai Biological Technology's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:5HB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:5HB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 27.3%
DB:5HB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 22.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:5HB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:5HB Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 2,504 787 626 3
2020-12-31 1,880 -328 429 1
2020-04-08
DB:5HB Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-12-31 1,604 371
2019-09-30 1,585 378
2019-06-30 1,565 302 386
2019-03-31 1,556 347 400
2018-12-31 1,546 391 415
2018-09-30 1,523 398 411
2018-06-30 1,501 404 408
2018-03-31 1,423 374 390
2017-12-31 1,345 343 372
2017-09-30 1,214 330 351
2017-06-30 1,083 317 329
2017-03-31 967 286 317

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Shanghai Haohai Biological Technology's earnings are expected to grow significantly at over 20% yearly.
  • Shanghai Haohai Biological Technology's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:5HB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Shanghai Haohai Biological Technology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5HB Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 3.64 4.45 2.83 2.00
2020-12-31 2.41 2.41 2.41 1.00
2020-04-08
DB:5HB Past Financials Data
Date (Data in CNY Millions) EPS *
2019-12-31 2.27
2019-09-30 2.34
2019-06-30 2.41
2019-03-31 2.50
2018-12-31 2.59
2018-09-30 2.57
2018-06-30 2.55
2018-03-31 2.44
2017-12-31 2.33
2017-09-30 2.19
2017-06-30 2.06
2017-03-31 1.98

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Shanghai Haohai Biological Technology is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Shanghai Haohai Biological Technology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Shanghai Haohai Biological Technology has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

5HB Past Performance

  How has Shanghai Haohai Biological Technology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Shanghai Haohai Biological Technology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Shanghai Haohai Biological Technology's year on year earnings growth rate has been positive over the past 5 years.
  • Shanghai Haohai Biological Technology's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Shanghai Haohai Biological Technology's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
Shanghai Haohai Biological Technology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Shanghai Haohai Biological Technology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5HB Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1,604.33 370.78
2019-09-30 1,584.85 378.23 367.26 53.81
2019-06-30 1,565.36 385.69 734.52 107.62
2019-03-31 1,555.59 400.11 736.00 101.49
2018-12-31 1,545.82 414.54 737.49 95.37
2018-09-30 1,523.31 411.30 714.70 89.33
2018-06-30 1,500.81 408.06 691.92 83.28
2018-03-31 1,422.83 390.24 650.38 79.81
2017-12-31 1,344.86 372.42 608.84 76.33
2017-09-30 1,214.10 350.86 555.42 67.49
2017-06-30 1,083.35 329.31 502.00 58.65
2017-03-31 967.25 317.18 439.98 52.95
2016-12-31 851.16 305.05 377.95 47.26
2016-09-30 787.45 294.58 357.61 43.73
2016-06-30 723.74 284.11 337.27 40.21
2016-03-31 693.83 278.79 319.13 37.73
2015-12-31 663.92 273.47 300.98 35.25
2015-09-30 630.34 258.16 277.97 31.84
2015-06-30 596.77 242.84 254.97 28.43
2015-03-31 556.35 213.21 245.56 27.45
2014-12-31 515.94 183.58 236.15 26.46
2014-09-30 482.45 168.99 221.26 27.30
2014-06-30 448.96 154.40 206.36 28.14
2014-03-31 425.02 147.96 191.95 25.83
2013-12-31 401.09 141.52 177.54 23.52

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Shanghai Haohai Biological Technology has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Shanghai Haohai Biological Technology used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Shanghai Haohai Biological Technology has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Shanghai Haohai Biological Technology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Shanghai Haohai Biological Technology has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

5HB Health

 How is Shanghai Haohai Biological Technology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Shanghai Haohai Biological Technology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Shanghai Haohai Biological Technology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Shanghai Haohai Biological Technology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Shanghai Haohai Biological Technology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 52.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Shanghai Haohai Biological Technology Company Filings, last reported 3 months ago.

DB:5HB Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31
2019-09-30 3,972.26 79.39 1,552.33
2019-06-30 3,972.26 42.46 1,552.33
2019-03-31 3,972.26 42.46 1,552.33
2018-12-31 3,835.45 36.66 1,459.10
2018-09-30 3,835.45 36.66 1,459.10
2018-06-30 3,546.37 39.00 1,398.73
2018-03-31 3,546.37 39.00 1,398.73
2017-12-31 3,385.26 37.48 1,855.06
2017-09-30 3,385.26 37.48 1,855.06
2017-06-30 3,140.51 25.17 1,804.16
2017-03-31 3,140.51 25.17 1,804.16
2016-12-31 2,985.86 26.67 2,112.89
2016-09-30 2,985.86 26.67 2,112.89
2016-06-30 2,731.62 0.00 2,212.48
2016-03-31 2,731.62 0.00 2,212.48
2015-12-31 2,665.43 0.00 2,190.13
2015-09-30 2,665.43 0.00 2,190.13
2015-06-30 2,530.26 0.00 2,071.73
2015-03-31 2,530.26 0.00 2,071.73
2014-12-31 594.16 0.00 195.23
2014-09-30 594.16 0.00 195.23
2014-06-30 612.21 0.00 204.82
2014-03-31 612.21 0.00 204.82
2013-12-31 530.58 0.00 204.23
  • Shanghai Haohai Biological Technology's level of debt (1.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Shanghai Haohai Biological Technology's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (712.3%, greater than 20% of total debt).
  • Shanghai Haohai Biological Technology earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Shanghai Haohai Biological Technology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Shanghai Haohai Biological Technology has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

5HB Dividends

 What is Shanghai Haohai Biological Technology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.84%
Current annual income from Shanghai Haohai Biological Technology dividends. Estimated to be 3.76% next year.
If you bought €2,000 of Shanghai Haohai Biological Technology shares you are expected to receive €37 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Shanghai Haohai Biological Technology's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.63%).
  • Shanghai Haohai Biological Technology's dividend is below the markets top 25% of dividend payers in Germany (4.61%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:5HB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:5HB Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 1.11 1.00
2020-12-31 0.93 1.00
2020-04-08
DB:5HB Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2019-04-25 0.500 1.357
2019-03-14 0.500 1.095
2019-02-01 0.500 1.280
2018-03-26 0.500 1.230
2017-06-23 0.500 1.517
2016-04-14 0.400 1.204
2016-03-21 0.400 1.072

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Shanghai Haohai Biological Technology has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Shanghai Haohai Biological Technology only paid a dividend in the past 4 years.
Current Payout to shareholders
What portion of Shanghai Haohai Biological Technology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Shanghai Haohai Biological Technology has not reported any payouts.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.3x coverage).
X
Income/ dividend checks
We assess Shanghai Haohai Biological Technology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Shanghai Haohai Biological Technology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Shanghai Haohai Biological Technology has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

5HB Management

 What is the CEO of Shanghai Haohai Biological Technology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jianying Wu
COMPENSATION CN¥1,445,000
AGE 55
TENURE AS CEO 9.8 years
CEO Bio

Dr. Jianying Wu has been General Manager and Executive Director of Shanghai Haohai Biological Technology Co., Ltd. since July 23, 2010. Mr. Wu worked as a surgeon at the General Surgery Department of the Second Affiliated Hospital of the Second Military Medical University. from 1991 to 1999. He worked at Shanghai Huayuan Life Sciences Research and Development Company Limited. (Shanghai Huayuan) from March 2003 to February 2004, at the Shanghai branch of China Huayuan Life Industry Limited. from February 2004 to May 2005 at Cinkate Pharmaceutical and Chemical Intermediates (Shanghai) Company Limited a company principally engaged in development and production of pharmaceutical and chemical intermediates, as well as selling its own products and providing relevant technical advisory services from May 2005 to July 2007. He served as the general manager at Haohai Limited from July 2007 to June 2010. He has been acting as the general manager at Shanghai Qisheng since August 2010, the general manager and executive director at Shanghai Likangrui since December 2010 and also the Chairman of Shanghai Baiyue since January 2015. He has been the Chairman of New Industries since November 2016 and the Executive director of Zhuhai Eye Good in December 2016. He served as vice chairman of Henan Universe since August 2015 and Executive Director of Haohai Development since February 2016, the Director of Haohai Healthcare Holdings (Cayman) Co., Ltd., a subsidiary of our Company since May 2016, the director of Haohai Healthcare Holdings (BVI) Co., Ltd. since August 2016, a subsidiary of our Company since May 2016. He serves as Director and general manager since July 2010 and was redesignated as an executive Director on 7 December 2014. He served as the Director of Haohai Healthcare since July 2015. Mr. Wu obtained a master's degree in clinical medicine from the Second Military Medical University in June 1997 and the practicing doctor qualification in the PRC in May 1999.

CEO Compensation
  • Jianying's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jianying's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Shanghai Haohai Biological Technology management team in years:

5.4
Average Tenure
48.5
Average Age
  • The average tenure for the Shanghai Haohai Biological Technology management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Yongtai Hou

TITLE
Chairman
COMPENSATION
CN¥1M
AGE
57
TENURE
9.8 yrs

Jianying Wu

TITLE
GM & Executive Director
COMPENSATION
CN¥1M
AGE
55
TENURE
9.8 yrs

Minjie Tang

TITLE
CFO & Executive Director
COMPENSATION
CN¥1M
AGE
44
TENURE
3.3 yrs

Yiyi Chen

TITLE
Executive Director
COMPENSATION
CN¥920K
AGE
37
TENURE
9.8 yrs

Caixia Ren

TITLE
Deputy General Manager
AGE
61
TENURE
9.8 yrs

Wenbin Wang

TITLE
Deputy General Manager
AGE
52
TENURE
1.1 yrs

Jundong Zhang

TITLE
Deputy General Manager
AGE
45
TENURE
1.1 yrs

Weidong Tao

TITLE
Deputy General Manager

Ming King Chiu

TITLE
Joint Company Secretary
AGE
41
TENURE
5.4 yrs

Min Tian

TITLE
Board Secretary & Joint Company Secretary
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Shanghai Haohai Biological Technology board of directors in years:

9.8
Average Tenure
50.5
Average Age
  • The tenure for the Shanghai Haohai Biological Technology board of directors is about average.
Board of Directors

Jianying Wu

TITLE
GM & Executive Director
COMPENSATION
CN¥1M
AGE
55
TENURE
9.8 yrs

Minjie Tang

TITLE
CFO & Executive Director
COMPENSATION
CN¥1M
AGE
44
TENURE
3.2 yrs

Yiyi Chen

TITLE
Executive Director
COMPENSATION
CN¥920K
AGE
37
TENURE
9.8 yrs

Hongbo Shen

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥84K
AGE
40
TENURE
5.5 yrs

Yongtai Hou

TITLE
Chairman
COMPENSATION
CN¥1M
AGE
57
TENURE
9.8 yrs

Qin Zhu

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥84K
AGE
55
TENURE
5.5 yrs

Yuanzhong Liu

TITLE
Chairman of the Supervisory Committee
AGE
50
TENURE
9.8 yrs

Jie You

TITLE
Non Executive Director
AGE
56
TENURE
9.8 yrs

Ming Ping Huang

TITLE
Non-Executive Director
COMPENSATION
CN¥825K
AGE
43
TENURE
9.8 yrs

Huabin Chen

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥84K
AGE
51
TENURE
5.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. Apr 20 Sell Morgan Stanley, Investment Banking and Brokerage Investments Company 01. Apr 20 01. Apr 20 -134,708 €3.66 €-493,134
20. Jan 20 Sell Prudence Investment Management (Hong Kong) Limited Company 15. Jan 20 15. Jan 20 -16,500 €5.44 €-89,690
22. Nov 19 Sell Matthews International Capital Management, LLC Company 20. Nov 19 20. Nov 19 -49,900 €5.31 €-264,961
18. Nov 19 Buy Dalton Investments LLC Company 12. Nov 19 12. Nov 19 204,300 €5.21 €1,064,156
14. Nov 19 Sell Matthews International Capital Management, LLC Company 12. Nov 19 12. Nov 19 -203,600 €5.18 €-1,054,938
08. Nov 19 Buy Dalton Investments LLC Company 05. Nov 19 05. Nov 19 2,191,800 €5.12 €11,211,327
08. Nov 19 Sell Matthews International Capital Management, LLC Company 06. Nov 19 06. Nov 19 -447,300 €5.17 €-2,310,739
05. Nov 19 Sell Prime Capital Management Company Limited Company 31. Oct 19 31. Oct 19 -19,300 €5.17 €-99,782
22. Oct 19 Buy Matthews International Capital Management, LLC Company 18. Oct 19 18. Oct 19 90,500 €5.07 €458,619
18. Oct 19 Sell Matthews International Capital Management, LLC Company 17. Oct 19 17. Oct 19 -58,900 €4.61 €-271,678
26. Jul 19 Sell UBS Asset Management Company 23. Jul 19 23. Jul 19 -16,000 €5.22 €-83,571
08. Jul 19 Sell Prime Capital Management Company Limited Company 03. Jul 19 03. Jul 19 -21,200 €4.94 €-104,669
26. Jun 19 Sell UBS Asset Management Company 21. Jun 19 21. Jun 19 -101,400 €4.99 €-505,726
25. Jun 19 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 20. Jun 19 20. Jun 19 64,097 €4.97 €318,785
24. Jun 19 Sell Prime Capital Management Company Limited Company 19. Jun 19 19. Jun 19 -31,000 €4.95 €-153,501
25. Apr 19 Buy Matthews International Capital Management, LLC Company 23. Apr 19 23. Apr 19 25,600 €6.83 €174,968
12. Apr 19 Sell Franklin Resources, Inc. Company 10. Apr 19 10. Apr 19 -48,400 €6.24 €-302,241
11. Apr 19 Sell Matthews International Capital Management, LLC Company 09. Apr 19 09. Apr 19 -39,900 €6.09 €-243,185
X
Management checks
We assess Shanghai Haohai Biological Technology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Shanghai Haohai Biological Technology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

5HB News

Simply Wall St News

5HB Company Info

Description

Shanghai Haohai Biological Technology Co., Ltd. engages in the research and development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. The company offers orthopedics, medical aesthetics and wound care; ophthalmology, and anti-adhesion and hemostasis products. It also provides medical sodium hyaluronate, medical chitosan, medical collagen sponge, and rhEGF, as well as biological reagents and materials. In addition, the company engages in the manufacture and sale of contact lens and intraocular lens materials, machines, and accessories; and investment and trading businesses. Further, it is involved in research and development of biological engineering and pharmaceutical products, related technology transfer, and consultation and service activities. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Details
Name: Shanghai Haohai Biological Technology Co., Ltd.
5HB
Exchange: DB
Founded: 2007
HK$1,527,610,547
177,828,400
Website: http://www.3healthcare.com
Address: Shanghai Haohai Biological Technology Co., Ltd.
WenGuang Plaza,
23rd Floor,
Shanghai,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 6826 Foreign Shares-Foreign Listed The Stock Exchange of Hong Kong Ltd. HK HKD 30. Apr 2015
DB 5HB Foreign Shares-Foreign Listed Deutsche Boerse AG DE EUR 30. Apr 2015
SHSE 688366 Domestic Shares Shanghai Stock Exchange CN CNY 30. Oct 2019
Number of employees
Current staff
Staff numbers
1,332
Shanghai Haohai Biological Technology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:20
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/21
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.